N/A
N=135
Reducing Disparities in Medication Adherence in SLE
Systemic Lupus Erythematosus
Bottom Line
View on ClinicalTrials.gov: NCT03738826 ↗Enrolled (actual)
135
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Feasibility as Measured by Number of Participants With EMR (Electronic Medical Record) Documentation of Adherence — 116 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Behavioral Intervention (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- Jun 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility as Measured by Number of Participants With EMR (Electronic Medical Record) Documentation of Adherence |
116 | — |
| PRIMARY Acceptability as Measured by Provider Survey |
4.4 | — |
| SECONDARY Medication Adherence as Determined by Self Report |
— | — |
| SECONDARY Percentage of Adherent Participants as Determined by Medication Possession Ratio (MPR) |
46; 55 | — |
Summary
This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus
Eligibility Criteria
Inclusion Criteria
- All followup patients seen at the Duke Lupus clinic
Exclusion Criteria
- Patients not seen at the Duke Lupus Clinic
- New patients seen for the first time at the Duke Lupus Clinic
- Patients who are not prescribed any lupus medications
Data sourced from ClinicalTrials.gov (NCT03738826). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.